Эпидемиология первичного гиперпаратиреоза


До середины 70-х годов XX века первичный гиперпаратиреоз (ПГПТ) считали крайне редким заболеванием. После введения в клиническую практику исследования уровня кальция крови, представления о его распространенности и многообразии клинических признаков претерпели значительные изменения. Представленный обзор литературы демонстрирует результаты немногочисленных исследований эпидемиологии ПГПТ, проведенных в различных странах.

Список литературы

1. Hedback G., Oden A. Death risk factor analysis in primary hyperparathyroidism. Eur J Clin Inv 1998;28:1011-1018.

2. The American Association of clinical endocrinologists and The American Association of endocrine surgeons. Position statement on the diagnosis and management of primary hyperparathyroidism. Endocrine Pract 2005;11:1.

3. DeLellis R.A., Mazzaglia P., Mangray S. Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 2008;132:8:1251-1262.

4. Adami S., Marcocci C., Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002;17:Suppl 2:N18-N23.

5. Ning Yu, Peter T. Donnan, Michael J. Murphy and Graham P. Leese. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. J Clin Endocrinol 2009;71:485-493.

6. Heath H., Hodgson S.F., Kennedy M.A. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. New Engl J Med 1980;302:189-193.

7. How to treat. Hyperparathyroidism. Australian doctor 2002;4-8.

8. Wermers R.A., Atkinson E.J, Achenbach S.J. et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:1:171-177.

9. Melton L.J. 3rd. Mayo Clinic, Rochester, Minnesota, USA. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Int Med 1997;126:6:433-440.

10. Morris A.D., Boyle D.I., MacAlpine R. et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. Br Med J 1997;315:524-528.

11. Flynn R.W., Macdonald T.M., Jung R.T. et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metabol 2006;91:2159-2164.

12. The Mattson Jack Group. Epidemiology of Primary Hyperparathyroidism in Europe - report commissioned by Amgen. 2003.

13. Blichert-Toft M., Mollerup C.L., Feldt-Rasmussen U.F. et al. [Primary hyperparathyroidism. An underdiagnosed disease in Denmark. Ugeskr Laeger 1993;155:765-769.

14. Nilsson I.L., Yin L., Lundgren E. et al. Clinical presentation of primary hyperparathyroidism in Europe -nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002;17:Suppl 2:N68.

15. Jorde R., Bonaa K.H., Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Tromso study. J Clin Epidemiol 2000;53:1164-1169.

16. Palmér M., Jakobsson S., Akerström G., Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Inv 1988;18:1:39-46.

17. Richerta L., Trombettia A., Herrmanna F.R. et al. Age and gender distribution of primary hyperparathyroidism and incidence of surgical treatment in a European country with a particularly high life expectancy. Swissmedwkly 2009;139:27-28.

18. Rubin M.R., Bilezikian J.P., McMahon, D.J. et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metabol 2008;93:3462-3470.

19. Polyzois Makras, Socrates E. Papapoulos Medical treatment of hypercalcaemia. Hormones 2009;8:2:83-95.

20. Bilezikian, JP, Silverberg, SJ, Shane, E, et al. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991;6:Suppl 2:S85.

21. Khan Bilezikian. Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ 2000;163:2.

22. Trump D., Farren B., Wooding C. et al. Clinical studies of multiple endocrine neoplasia type 1 (MENI). Q J Med 1996;89:653-669.

23. Beers M.H., Berkow R. (Eds.). The Merck manual of diagnosis and therapy. 17th ed. West Point, PA. Merck & Co Inc 1999.

24. Brandi M.L., Gagel R.F., Angeli A. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86.

25. Uchino S., Noguchi S., Sato M. et al. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res 2000;60:5553-5557.

26. Marx S.J. Multiple endocrine neoplasia type 1. In: The metabolic and molecular bases of inherited disease. Eds. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle. 8-th. New York: McGraw-Hill 2001;943-966.

Для цитирования:

., ., ., . Эпидемиология первичного гиперпаратиреоза. Проблемы Эндокринологии. 2010;56(5):3-7.

For citation:

Dedov I.I., Vasil'eva T.O., Rozhinskaia L.I., Mokrysheva N.G. Epidemiology of primary hyperparathyroidism. Problems of Endocrinology. 2010;56(5):3-7. (In Russ.)

Просмотров: 9

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)